The Pharma Letter: Huge potential for oral insulin candidate, says Oramed CEO Nadav Kidron
Despite an inexorable rise in the global population of type 2 diabetics, linked to changing lifestyle… Read the full article on www.thepharmaletter.com
Lake Forest Patch: OC Oral Insulin Clinical Trial Could Be Next Step For Treatment
This Tustin based Oral Insulin clinical trial in Orange County will test treatment for those with type 2 diabetes over the next 90 days. Read the full article on patch.com
New Atlas: Oral insulin proving successful in human clinical trials
For decades researchers have worked to find a way to orally administer insulin effectively to patients with diabetes. Now this game-changing treatment is one step closer to reality, with pharmaceutical company Oramed embarking on a final Phase 2b human clinical trial to prove the efficacy of its oral insulin before moving to the final stages […]
B2B News Network: Inside The Mind Of . . . Nadav Kidron
Nadav Kidron serves as Chief Executive Officer of Oramed Pharmaceuticals, which he co-founded in 2006. Their orally-taken insulin is game-changing technology that could revolutionize the way millions people with diabetes administer their medication. Read the full article on b2bnn.com
WKYC: Nadav Kidron-Oramed Pharmaceuticals is Changing The Lives of Diabetic Patients
Millions of diabetics inject insulin daily, and millions more are on the path to injections. But Oramed Pharmaceuticals aims to change that reality, with an insulin pill. Currently in clinical trials, the oral insulin capsule could radically change how we treat diabetes, and dramatically change the lives of diabetic patients. Oramed Pharmaceuticals CEO Nadav Kidron […]
Forbes: AI And Radar: The Future Of Noninvasive Blood Sugar Monitoring?
The “wish list”, or holy grail for diabetics who prick their finger several times a day to measure their blood sugar usually involves two things: a way to check their blood sugar without painful finger pricks, and taking a pill instead of an insulin shot. Read the full article on Forbes.com
